Group 1 - The company has established a remote diagnostic network covering over 2,700 hospitals nationwide, leveraging the "China Digital Pathology Remote Diagnosis and Quality Control Platform" from the National Health Commission [2][3] - The company has accumulated over 2 million typical case digital pathology slice data [2][3] - The company is collaborating with domestic enterprises to develop a "Pathology Auxiliary Diagnosis System" aimed at addressing the shortage of pathology doctors and limited diagnostic experience in grassroots hospitals [2][3]

证券日报网讯 1月23日，麦克奥迪在互动平台回答投资者提问时表示，公司的医疗产品主要包括细胞 DNA倍体分析系统、结核杆菌自动筛查系统、疟原虫自动诊断系统及免疫组化分析系统。公司联合国 内企业共同开发"病理辅助诊断系统"，希望通过辅助系统逐步解决基层医院病理医生资源不足、诊断经 验有限的痛点。 （文章来源：证券日报） ...

Core Viewpoint - The company is actively developing AI medical solutions to address challenges in pathology diagnosis, particularly in resource-limited settings [1] Group 1: Company Initiatives - The company's medical products include cell DNA ploidy analysis systems, automated screening systems for tuberculosis, automated diagnostic systems for malaria, and immunohistochemistry analysis systems [1] - The company is collaborating with domestic enterprises to develop a "pathology auxiliary diagnosis system" aimed at alleviating the shortage of pathology doctors and limited diagnostic experience in grassroots hospitals [1]

证券日报网讯1月16日，麦克奥迪（300341）在互动平台回答投资者提问时表示，公司的医疗产品主要 包括细胞DNA倍体分析系统、结核杆菌自动筛查系统、疟原虫自动诊断系统及免疫组化分析系统。公 司联合国内企业共同开发"病理辅助诊断系统"，希望通过辅助系统逐步解决基层医院病理医生资源不 足、诊断经验有限的痛点。公司目前没有与蚂蚁阿福存在合作关系。 ...